Do you want to read an article? Please log in or register.
Effect of sotagliflozin on major adverse cardiovascular events: a prespecified secondary analysis of the SCORED randomised trial
Cardiovascular Risk and Diseases
Related content
Cardiovascular Risk and Diseases
Bempedoic Acid Reduces the Risk of Major Adverse Cardiovascular Events Across Patient Subgroups
Cardiovascular Risk and Diseases
Effect of gastric bypass versus sleeve gastrectomy on the remission of type 2 diabetes, weight loss, and cardiovascular risk factors at 5 years (Oseberg): secondary outcomes of a single-centre, triple-blind, randomised controlled trial
Lancet Diabetes Endocrinol
Hauge JW, Borgeraas H, Birkeland KI, Johnson LK, Hertel JK, Hagen M, Gulseth HL, Lindberg M, Lorentzen J, Seip B, Kolotkin RL, Svanevik M, Valderhaug TG, Sandbu R, Hjelmesæth J, Hofsø D
doi: 10.1016/S2213-8587(24)00396-6
RECOMMENDED
Cardiovascular Risk and DiseasesFurther Publications
Carotid Plaque Score is Associated with 10-year Major Adverse Cardiovascular Events in Low-Intermediate Risk Patients Referred to a General Cardiology Community Clinic
★ 2
Recommended by
Prof. Dr Isabella Sudano, Faculty Member
Eur Heart J Cardiovasc Imaging
Matangi MF, Hétu MF, Armstrong DWJ, Shellenberger J, Brouillard D, Baker J, Johnson A, Grubic N, Willms H, Johri AM
doi: 10.1093/ehjci/jeae153
Further Publications
Aspirin Dosing for Secondary Prevention of Atherosclerotic Cardiovascular Disease in Male and Female Patients: A Secondary Analysis of the ADAPTABLE Randomized Clinical Trial
JAMA Cardiol
Benziger CP, Stebbins A, Wruck LM, Effron MB, Marquis-Gravel G, Farrehi PM, Girotra S, Gupta K, Kripalani S, Munoz D, Polonsky TS, Sharlow A, Whittle J, Harrington RA, Rothman RL, Hernandez AF, Jones WS
doi: 10.1001/jamacardio.2024.1712
Further Publications
Contribution of Clinical Trial Event Data by Data Source: A Prespecified Analysis of the ADAPTABLE Randomized Clinical Trial
JAMA Cardiol
Rymer JA, Mulder H, Wruck LM, Muñoz D, Kripalani S, Effron MB, Gupta K, Handberg E, Jain S, Girotra S, Whittle J, Hess R, Benziger CP, Knowlton KU, Curtis LH, Roe MT, Hammill BG, Rothman RL, Harrington R, Hernandez A, Jones WS
doi: 10.1001/jamacardio.2024.2019
RECOMMENDED
Heart, Artery and Coronary Diseases
Course of the effects of LDL-cholesterol reduction on cardiovascular risk over time: A meta-analysis of 60 randomized controlled trials
★ 3
Recommended by
Prof. Dr Isabella Sudano, Faculty Member
Atherosclerosis
Burger PM, Dorresteijn JAN, Koudstaal S, Holtrop J, Kastelein JJP, Jukema JW, Ridker PM, Mosterd A, Visseren FLJ
doi: 10.1016/j.atherosclerosis.2024.118540
Cardiovascular Risk and DiseasesFurther Publications
Sodium Glucose Co-transporter 2 Inhibitors and Major Adverse Cardiovascular Outcomes: A SMART-C Collaborative Meta-Analysis
Circulation
Patel SM, Kang YM, Im K, Neuen BL, Anker SD, Bhatt DL, Butler J, Cherney DZI, Claggett BL, Fletcher RA, Herrington WG, Inzucchi SE, Jardine MJ, Mahaffey KW, McGuire DK, McMurray JJV, Neal B, Packer M, Perkovic V, Solomon SD, Staplin N, Vaduganathan M, Wanner C, Wheeler DC, Zannad F, Zhao Y, Heerspink HJL, Sabatine MS, Wiviott SD
doi: 10.1161/CIRCULATIONAHA.124.069568
Heart Failure
Estimated Long-Term Benefits of Finerenone in Heart Failure: A Prespecified Secondary Analysis of the FINEARTS-HF Randomized Clinical Trial
JAMA Cardiol
Vaduganathan M, Claggett BL, Desai AS, Jhund PS, Lam CSP, Senni M, Shah SJ, Voors AA, Zannad F, Pitt B, Borentian M, Lay-Flurrie J, Viswanathan P, Behmenburg FU, McMurray JJV, Solomon SD
doi: 10.1001/jamacardio.2024.3782
COMMENTED
Heart Failure
Semaglutide in obesity-related heart failure with preserved ejection fraction and type 2 diabetes across baseline HbA(1c) levels (STEP-HFpEF DM): a prespecified analysis of heart failure and metabolic outcomes from a randomised, placebo-controlled trial
★ 1
Recommended and commented by
Prof. emer. Dr Ulrich Keller, Faculty Member
★ 2
Recommended by
Prof. Dr Isabella Sudano, Faculty Member
Lancet Diabetes Endocrinol
Davies MJ, van der Meer P, Verma S, Patel S, Chinnakondepalli KM, Borlaug BA, Butler J, Kitzman DW, Shah SJ, Harring S, Salsali A, Rasmussen S, von Lewinski D, Abhayaratna W, Petrie MC, Kosiborod MN, STEP-HFpEF Trials Committees and Investigators
doi: 10.1016/S2213-8587(24)00304-8